Navigation Links
Imaging gives clearer picture of cancer drugs' chances of success
Date:4/28/2014

The quest for new cancer treatments could be revolutionised by advances in technology that can visualise living cells and tissues, scientists claim.

Leading edge imaging techniques will make it easier to identify which are the most promising new drugs to take forward for patient testing, a review of the technology suggests.

Applying such techniques early in the drug discovery process could improve the success rate of new medicines by helping to rule out drugs that are unlikely to work.

Researchers at the University of Edinburgh are leading the way in using biological imaging to make the development of new cancer treatments more efficient.

Recent advances mean that scientists can now check how experimental drugs are working inside living cells and in real time.

Using automated microscopes to track fluorescent dyes, researchers can rapidly test thousands of potential drugs in different cancer cell types to find the most promising new treatments.

This pioneering approach known as phenotypic drug discovery monitors the effect of a trial drug on the disease as a whole rather than its impact on an individual target protein, which has been the approach until now.

Writing in the journal Nature Reviews Cancer, scientists argue that the new technologies will help to better predict how a drug will work in real life, not just in the test tube.

Currently, just five per cent of drugs tested in clinical trials are approved as therapies for patients. Often drugs do not work in a person as they do in an artificial environment. Sometimes treatments have unexpected side effects that are only picked up in the later stages of the development process.

Report author Dr Neil Carragher, of the Edinburgh Cancer Research UK Centre at the University of Edinburgh, said: "The drug discovery process is hugely expensive and inefficient. In Edinburgh we are leading the way in using biological imaging to streamline the process, allowing us to better select drug candidates with the lowest risk of side effects and the best chances of success in treating patients."


'/>"/>

Contact: Jen Middleton
jen.middleton@ed.ac.uk
44-131-650-6514
University of Edinburgh
Source:Eurekalert  

Related medicine news :

1. Neuroimaging: Live from inside the cell
2. Live cell imaging reveals distinct alterations of subcellular glutathione potentials
3. Tumors light up with new, unique imaging system using scorpion venom protein and a laser
4. Using susceptibility-weighted imaging to study concussion in college ice hockey players
5. A silk coat for diamonds makes sleek new imaging and drug delivery tool
6. New biomedical diagnostics using personalized 3-D imaging
7. North Shore-LIJ Completes Last Phase of $50M Upgrade of its Diagnostic Imaging Systems, $12M for GE Low-Dose CT Scanners to Reduce Patients’ Radiation Exposure
8. Olea Medical® Receives FDA 510(k) Clearance for Olea Sphere v2.3 Medical Imaging Software
9. Chemical imaging brings cancer tissue analysis into the digital age
10. Thermal Imaging Market (Solutions & Applications) Worth $5.84 Billion by 2018 - New Report by MarketsandMarkets
11. Pre-Clinical Imaging (In Vivo) Market worth $1.55 Billion by 2017 - New Report by MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Imaging gives clearer picture of cancer drugs' chances of success
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... ... 08, 2016 , ... The schedule is now online for the ... Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues ... and causes of chronic illness in children. , Very recent articles have cited 1 ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... report published by Allied Market Research titled, "World ... and Forecasts, 2014-2020", estimates the world synthetic biology ... synthesis and sequencing technology segment would continue to ... software tools segment, collectively, held around half of ...
(Date:2/5/2016)... N.C. , Feb. 5, 2016  Despite the ... been slower than other industries to embrace Big Data ... with utilization. On the medical side, organizations have begun ... everything from clinical trials to adherence. ... from benchmarking firm Best Practices, LLC, Big Data has ...
(Date:2/5/2016)... 5, 2016  Syneron Medical Ltd. (NASDAQ: ... announced today that William Griffing , Chief ... scheduled to participate in the Leerink Partners 5 ... 11, 2016 in New York City ... to meet with the Mr. Griffing and will ...
Breaking Medicine Technology: